8-K - Aardvark Therapeutics, Inc. (0001774857) (Filer)
Published . Updated .
Key takeaways
- 8-K - Aardvark Therapeutics filed an 8-K with the SEC on Nov 13 (a notice of a material company event).
- Exposed: AARD
- Market reaction: price tracking starts with the next trading session.
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.
8-K - Aardvark Therapeutics filed an 8-K with the SEC on Nov 13 (a notice of a material company event).
Directly affected
- AARD Aardvark Therapeutics
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR holds the health sector that Aardvark Therapeutics belongs to, so it often moves with news about it.
- LLY Eli Lilly and
Eli Lilly and is a peer of Aardvark Therapeutics in pharmaceutical preparations; rivals often move on the same news.
- JNJ Johnson & Johnson
Johnson & Johnson is a peer of Aardvark Therapeutics in pharmaceutical preparations; rivals often move on the same news.
- ABBV AbbVie
AbbVie is a peer of Aardvark Therapeutics in pharmaceutical preparations; rivals often move on the same news.
- MRK Merck
Merck is a peer of Aardvark Therapeutics in pharmaceutical preparations; rivals often move on the same news.
- ABT Abbott Laboratories
Abbott Laboratories is a peer of Aardvark Therapeutics in pharmaceutical preparations; rivals often move on the same news.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| AARD | -25.16% | -12.26% | base | after close | after close | after close | after close |
| XLV | -1.60% | +0.57% | base | after close | after close | after close | after close |
| LLY | -5.27% | +0.16% | base | after close | after close | after close | after close |
| JNJ | -2.55% | -0.98% | base | after close | after close | after close | after close |
| ABBV | -1.00% | -0.21% | base | after close | after close | after close | after close |
| MRK | -0.13% | +0.71% | base | after close | after close | after close | after close |
| ABT | +2.53% | +2.97% | base | after close | after close | after close | after close |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Filed: 2026-11-13 AccNo: 0001193125-26-459373 Size: 315 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Source: sec-edgar
The price since 13 Nov 2026: Aardvark Therapeutics (AARD) versus the S&P 500
| Company | When | Move | Status |
|---|---|---|---|
| Aardvark Therapeutics (AARD) | three days earlier | -12.26% | final price |
| Aardvark Therapeutics (AARD) | five days earlier | -25.16% | final price |
| ABBV | three days earlier | -0.21% | final price |
| ABBV | five days earlier | -1.00% | final price |
| ABT | three days earlier | +2.97% | final price |
| ABT | five days earlier | +2.53% | final price |
| JNJ | three days earlier | -0.98% | final price |
| JNJ | five days earlier | -2.55% | final price |
| LLY | three days earlier | +0.16% | final price |
| LLY | five days earlier | -5.27% | final price |
| MRK | three days earlier | +0.71% | final price |
| MRK | five days earlier | -0.13% | final price |
| XLV | three days earlier | +0.57% | final price |
| XLV | five days earlier | -1.60% | final price |
Congressional trades in the stocks in this story
- Rep. Gilbert Cisneros bought Eli Lilly (LLY), worth $1,001 - $15,000 on 20 Oct 2026. That is 24 days before publication. Filed 10 Nov 2026. View the filing.
- Rep. Rohit Khanna bought Eli Lilly (LLY) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 70 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna sold Johnson & Johnson (JNJ) (held by a spouse), worth $15,001 - $50,000 on 7 Oct 2026. That is 37 days before publication. Filed 5 Nov 2026. View the filing.
- Rep. Thomas H. Kean Jr sold Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 30 Sep 2026. That is 44 days before publication. Filed 30 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Johnson & Johnson (JNJ) (held by a spouse), worth $1,001 - $15,000 on 25 Sep 2026. That is 49 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna bought AbbVie (ABBV) (held by a spouse), worth $1,001 - $15,000 on 7 Oct 2026. That is 37 days before publication. Filed 5 Nov 2026. View the filing.
- Rep. Pete Sessions sold AbbVie (ABBV), worth $15,001 - $50,000 on 14 Sep 2026. That is 60 days before publication. Filed 18 Sep 2026. View the filing.
- Rep. Rohit Khanna sold AbbVie (ABBV) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 70 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar sold Merck (MRK), worth $1,001 - $15,000 on 24 Sep 2026. That is 50 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar bought Merck (MRK), worth $15,001 - $50,000 on 19 Aug 2026. That is 86 days before publication. Filed 9 Sep 2026. View the filing.
- Rep. Rohit Khanna bought Abbott Laboratories (ABT) (held by a spouse), worth $1,001 - $15,000 on 7 Oct 2026. That is 37 days before publication. Filed 5 Nov 2026. View the filing.
- Rep. Pete Sessions sold Abbott Laboratories (ABT) (held by a spouse), worth $50,001 - $100,000 on 2 Oct 2026. That is 42 days before publication. Filed 27 Oct 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who is named in “8-K - Aardvark Therapeutics, Inc. (0001774857) (Filer)”
Companies mentioned with this story
- AARD Aardvark Therapeutics
Aardvark Therapeutics (AARD) is linked, with no stored direction, high confidence in the 13 Nov 2026 story “8-K - Aardvark Therapeutics, Inc. (0001774857) (Filer).” Reason on file: SEC 8-K filing -> direct issuer disclosure -> AARD
How “8-K - Aardvark Therapeutics, Inc. (0001774857) (Filer)” reaches Aardvark Therapeutics (AARD)
Aardvark Therapeutics (AARD) is the company in “8-K - Aardvark Therapeutics, Inc. (0001774857) (Filer),” the 13 Nov 2026 this story story.
What ties Aardvark Therapeutics (AARD) to the headline is this: SEC 8-K filing -> direct issuer disclosure -> AARD
Dates in the story, and the Aardvark Therapeutics (AARD) price range
AARD traded between 0.94 and 4.49 across 20 sessions. The latest close on file is 1.59.
How strong the case is around Aardvark Therapeutics (AARD)
14 out of 100
“8-K - Aardvark Therapeutics, Inc. (0001774857) (Filer)” scores 14 out of 100. The score uses 1 sources, and 1 linked companies.